■在这篇文献综述中,我们描述了印度尼西亚NBS计划(主要集中在CH筛查上)的进展,其目前的试点项目,以及这个计划的未来。
■由于其概念始于先天性甲状腺功能减退症(CH)筛查,印度尼西亚在国家统计局取得了缓慢的进展。缺少讨论历史的文学,或者缺乏,NBS在印度尼西亚的旅程。
■我们在Pubmed和GoogleScholar中搜索了诸如“新生儿筛查”等关键词的文献。“新生儿筛查,\"\"印度尼西亚,\"\"亚太地区,\"\"先天性甲状腺功能减退症,先天性肾上腺增生,严重的先天性心脏病,\"\"听力损失,“和”天生的代谢错误。\"
■印度尼西亚唯一强制性和受监管的NBS计划是先天性甲状腺功能减退(CH)筛查,随着一些试点项目正在进行筛查先天性肾上腺增生(CAH),危重型先天性心脏病(CCHD),听力损失,在较小程度上,先天性代谢错误(IEM)。
■尽管有证据和好处,政府没有强制或监管新生儿疾病,如CHD,CAH,听力损失,和IEM。尽管多个试点项目和研究表明,至少尝试筛查新生儿的这些条件是有益的,但缺乏监管。
UNASSIGNED: In this literature review, we describe the progress of Indonesia\'s NBS program (which is heavily centered on CH screening), its current pilot projects, and what lies ahead for this program.
UNASSIGNED: Since its conception began with congenital hypothyroidism (CH) screening, Indonesia has experienced plodding progress in NBS. There is a shortage of literature discussing the history, or the lack of, and journey of NBS in Indonesia.
UNASSIGNED: We searched for literature in Pubmed and Google Scholar with keywords such as \"Newborn Screening, \"Neonatal Screening,\" \"Indonesia,\" \"Asia Pacific,\" \"Congenital Hypothyroidism,\" \"Congenital Adrenal Hyperplasia,\"\"Critical Congenital Heart Disease,\" \"Hearing Loss,\" and \"Inborn Error of Metabolism.\"
UNASSIGNED: The only mandatory and regulated NBS program in Indonesia is congenital hypothyroid (CH) screening, with some pilot projects being conducted on screening for congenital adrenal hyperplasia (CAH), critical congenital heart disease (CCHD), hearing loss, and to a lesser extent, inborn error of metabolisms (IEMs).
UNASSIGNED: Despite the evidence and benefits, the government does not mandate or regulate newborn diseases such as CHD, CAH, hearing loss, and IEMs. The lack of regulation exists despite multiple pilot projects and studies showing a benefit in at least trying to screen newborns for those conditions.